Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04280549 · ClinicalTrials.gov registry record
Platelet PAR-1 Activation in Health and Diabetes
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 100
- Enrollment target
NCT04280549: Completed study, sponsored by Vanderbilt University Medical Center.
NCT04280549 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04280549 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe peripheral artery disease. We seek, through this project, to understand PAR-1 activation in persons without peripheral artery disease. As many patients with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will be determined using platelet aggregation experiments and assessment of platelet-monocyte aggregates in peripheral blood.
Primary Outcome
Number of dilysyl-MDA cross-links formed in human platelets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2021-02-02 |
What the finished NCT04280549 record still lists
NCT04280549 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04280549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04280549 about?
NCT04280549 is a clinical study titled "Platelet PAR-1 Activation in Health and Diabetes". Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe periph...
What is the current status of trial NCT04280549?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2018-06-01. Estimated completion is 2021-02-02.
Who is sponsoring clinical trial NCT04280549?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI